MASSARELLI, ILARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.442
EU - Europa 803
AS - Asia 265
AF - Africa 71
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 2.583
Nazione #
US - Stati Uniti d'America 1.388
IT - Italia 224
CN - Cina 153
DE - Germania 116
SE - Svezia 105
GB - Regno Unito 76
BG - Bulgaria 73
AT - Austria 56
CA - Canada 54
UA - Ucraina 54
TR - Turchia 47
SG - Singapore 31
CH - Svizzera 29
CI - Costa d'Avorio 28
FI - Finlandia 28
SN - Senegal 27
FR - Francia 25
VN - Vietnam 21
NG - Nigeria 16
RU - Federazione Russa 11
HK - Hong Kong 6
IN - India 5
BE - Belgio 2
IR - Iran 2
CZ - Repubblica Ceca 1
ES - Italia 1
EU - Europa 1
LU - Lussemburgo 1
PE - Perù 1
PT - Portogallo 1
Totale 2.583
Città #
Ann Arbor 234
Woodbridge 221
Chandler 152
Houston 149
Milan 105
Jacksonville 91
Fairfield 77
Sofia 73
Ashburn 63
Beijing 63
Vienna 56
Ottawa 49
Izmir 46
New York 40
Wilmington 39
Florence 36
Nanjing 34
Lancaster 32
Bern 29
Abidjan 28
Princeton 28
Dakar 27
Lawrence 27
Seattle 26
Cambridge 23
London 21
Jüchen 20
Marseille 20
Lagos 16
Medford 14
Nanchang 14
Dearborn 11
Des Moines 11
Dong Ket 11
Shenyang 11
Singapore 11
Boulder 9
Rome 9
Tianjin 7
Falls Church 6
Hong Kong 6
Orange 6
Auburn Hills 5
Pune 5
Bremen 4
Changsha 4
Kunming 4
Ogden 4
San Diego 4
Toronto 4
Jiaxing 3
Los Angeles 3
Norwalk 3
Verona 3
Washington 3
Brussels 2
Changchun 2
Hangzhou 2
Hebei 2
Hefei 2
Kansas City 2
Redwood City 2
San Francisco 2
Tehran 2
Boardman 1
Bovisio Masciago 1
Charlotte 1
Council Bluffs 1
Dallas 1
Forlimpopoli 1
Hanoi 1
Helsinki 1
Indiana 1
Jinan 1
Jinhua 1
Leawood 1
Lima 1
Lisbon 1
Luxembourg 1
Milton Keynes 1
Montreal 1
Munich 1
Ningbo 1
Nürnberg 1
Phoenix 1
Prague 1
Sant'elpidio A Mare 1
Sassari 1
Shotts 1
Taiyuan 1
Tappahannock 1
Varenguebec 1
Totale 2.046
Nome #
Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells 192
IN VITRO ANTICANCER ACTIVITY OF E. PALLIDA POLYACETILENES 164
Design of fibrin-specific ligands for drug targeting 145
Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors 136
Development of Classification Model batteries for predicting inhibition of tubulin polymerization by small molecules 134
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals 117
Binding mode of Adenosine Deaminase inhibitors and zinc modeling 116
Optimizing QSAR Models for Predicting Ligand Binding to the Drug-Metabolizing Cytochrome P450 Isoenzyme CYP2D6 115
Nanoparticles for smart drug delivery system: computational approach for the design of fibrinolytic drugs 114
Characterization of enzyme kinetics of human Cathepsin L 104
Development of QSAR models for predicting inhibition of tubulin polymerization in the design of anticancer drugs 99
Prediction of HERG Potassium Channel Affinity by Traditional QSAR and Volsurf Approach 97
Ligand Design for the g(312-324) epitope of fibrin 95
QSAR models for predicting biological properties, developed by combining structure- and ligand-based approaches: an application to the hERG potassium channel inhibition 91
Insights into interactions between fibrin and peptidic ligands 86
Understanding mechanism of selectivity between Gal- and Man-type ligands showed by human asialoglycoprotein receptor in view of predicting its interactions with exogenous sugars 86
HIGH-THROUGHPUT DOCKING AS A TOOL FOR VIRTUAL SCREENING AND FLUORIMETRIC ASSAYS AIMED AT IDENTIFYING FIBRIN LIGANDS 84
New applications in cancer therapy: design of ligands for cathepsin L 78
Computational studies of human Cathepsin L inhibition 77
Theoretical Studies of Interactions between Chelidocystatin and human Cathepsins for potential applications in cancer therapy 73
Identification of selective ligands for human fibrin recognition by means of High-Throughput Docking 73
Understanding selectivity mechanism of human asialoglycoprotein receptor (ASGP-R) toward Gal- and Man-type ligands for predicting interactions with exogenous sugars 63
STUDI TEORICI D’INTERAZIONE TRA NUOVI COMPOSTI E CATEPSINA L UMANA PER POTENZIALI APPLICAZIONI NELLA TERAPIA ONCOLOGICA 62
Design of Highly Specified Ligands of Fibrin for Therapeutic Applications 59
Three-dimensional models of the oligomeric human Asialoglycoprotein Receptor (ASGP-R) 51
Computer-Aided Design of Fibrin-Specific Liganda and Preliminary Experimental Validation 46
Studio d’ interazione dell’ epitopo g(312-324) della fibrina umana con ligandi peptidici 34
Totale 2.591
Categoria #
all - tutte 6.120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.120


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020338 60 40 9 13 31 25 30 17 32 40 39 2
2020/2021129 24 3 14 3 21 1 17 12 4 5 3 22
2021/2022231 3 22 2 10 52 34 5 8 8 2 16 69
2022/2023543 40 66 40 43 77 66 2 25 129 0 43 12
2023/2024342 65 50 46 22 51 63 4 4 5 1 7 24
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 2.591